Omeros (NASDAQ:OMER) Given "Buy" Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Omeros (NASDAQ:OMER - Free Report) in a research note published on Wednesday,Benzinga reports. The brokerage currently has a $36.00 target price on the biopharmaceutical company's stock.

Several other brokerages have also recently issued reports on OMER. StockNews.com cut shares of Omeros from a "hold" rating to a "sell" rating in a research report on Wednesday, April 9th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Omeros currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Price Performance

Shares of OMER traded down $1.87 during mid-day trading on Wednesday, reaching $4.32. The stock had a trading volume of 4,289,171 shares, compared to its average volume of 606,781. Omeros has a 52-week low of $3.00 and a 52-week high of $13.60. The business's fifty day moving average is $7.43 and its 200 day moving average is $8.18. The firm has a market cap of $251.59 million, a price-to-earnings ratio of -1.88 and a beta of 2.42.

Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.71) by $0.08. During the same quarter last year, the firm posted ($0.15) earnings per share. As a group, sell-side analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Institutional Trading of Omeros

A number of large investors have recently made changes to their positions in the company. Jane Street Group LLC raised its holdings in Omeros by 15.9% during the third quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company's stock worth $231,000 after purchasing an additional 8,010 shares in the last quarter. Barclays PLC raised its holdings in Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock worth $376,000 after purchasing an additional 51,873 shares in the last quarter. SG Americas Securities LLC raised its holdings in Omeros by 21.2% during the fourth quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company's stock worth $241,000 after purchasing an additional 4,257 shares in the last quarter. Seros Financial LLC acquired a new stake in Omeros during the fourth quarter worth approximately $159,000. Finally, Stordahl Capital Management Inc. acquired a new stake in Omeros during the fourth quarter worth approximately $395,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.